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Summary
Background: The inflammatory bowel diseases, Crohn's disease and ulcerative colitis 
are related multifactorial diseases. Their pathogenesis is influenced by each individ-
ual's immune system, the environmental factors within exposome and genetic pre-
disposition. Smoking habit is the single best-established environmental factor that 
influences disease phenotype, behaviour and response to therapy.
Aim: To assess current epidemiological, experimental and clinical evidence that may 
explain how smoking impacts on the pathogenesis of inflammatory bowel disease.
Methods: A Medline search for 'cigarette smoking', in combination with terms in-
cluding ‘passive’, ‘second-hand’, 'intestinal inflammation', ‘Crohn's disease’, ‘ulcerative 
colitis’, 'colitis'; 'intestinal epithelium', ‘immune system', 'intestinal microbiota', ‘tight 
junctions’, ‘mucus’, ‘goblet cells’, ‘Paneth cells’, ‘autophagy’; ‘epigenetics’, ‘genes’, 
‘DNA methylation’, ‘histones’, ‘short noncoding/long noncoding RNAs’; ‘carbon mon-
oxide/CO’ and ‘nitric oxide/NO’ was performed.
Results: Studies found evidence of direct and indirect effects of smoking on various 
parameters, including oxidative damage, impairment of intestinal barrier and immune 
cell function, epigenetic and microbiota composition changes, that contribute to the 
pathogenesis of inflammatory bowel disease.
Conclusions: Cigarette smoking promotes intestinal inflammation by affecting 
the function and interactions among intestinal epithelium, immune system and 
microbiota/microbiome.
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1  | INTRODUC TION
The detrimental effect of cigarette smoking on cardiovascular and 
pulmonary disease has long been recognised: the first review de-
scribing the effects of cigarette smoking on physiological parame-
ters, such as peripheral blood flow, heart rate and body temperature 
was published in 1946.1 Despite legislation prohibiting cigarette 
smoking in the workplace and public buildings in most western coun-
tries, it remains a major risk factor for numerous life-threatening, 
noncommunicable diseases, such as coronary heart disease2,3 and 
many cancers4,5 and for inflammatory disorders, such as asthma,6 
chronic obstructive pulmonary disease,7,8 idiopathic pulmonary fi-
brosis,9,10 multiple sclerosis11 and psoriasis.12
Smoking has been also correlated with inflammatory bowel 
disease.13-15 Inflammatory bowel disease is a chronic inflammatory 
disorder of the gut which encompasses Crohn's disease and ulcer-
ative colitis.16,17 Crohn's disease was first described in the early 19th 
century since when, its global prevalence has steadily risen, in line 
with industrialisation and urbanisation (for a recent review see 18). 
Inflammatory bowel disease is a multifactorial disease, influenced by 
each individual's characteristics, such as the immune system, their 
microbiome and genetic predispositions and their ‘exposome’, ie the 
environmental factors that an individual has been exposed to. The 
strongest environmental risk factor for the development and pro-
gression of Crohn's disease is cigarette smoking.19 Conversely, it is 
perceived that smoking exerts protective effects on the develop-
ment and progression of ulcerative colitis.20,21 Understanding the 
effect of smoking is complex because inhaled smoke contains over 
5000 ingredients and amongst these, ~100 compounds are known 
to have toxic or carcinogenic effects.22 Cigarette smoking affects 
the integrity of the gut epithelium, the immune responses, the di-
versity and composition of the gut microbiota and causes epigenetic 
modifications influencing gene expression.23-25
This review discusses the wealth of emerging evidence char-
acterising the effects of smoking on various cell types and physi-
ological processes within the intestinal epithelium, and how these 
mechanistic actions play an important role in determining suscep-
tibility to, and disease course of, inflammatory bowel disease. We 
also define a research agenda for the next decade to address the 
key unresolved issues, for both Crohn's disease and ulcerative colitis.
1.1 | Smoking and inflammatory bowel disease—
clinical epidemiology
The incidence and prevalence of inflammatory bowel disease are 
increasing globally, with the highest relative increase observed in 
developing and recently developed nations.26 Studies of immigrants 
moving from a country with low incidence of inflammatory bowel 
disease to one with higher incidence of inflammatory bowel disease, 
have suggested higher risk of developing inflammatory bowel dis-
ease, particularly for second-generation immigrants and younger in-
dividuals.27 This phenomenon is attributed mainly to ‘westernisation’ 
of lifestyle and key environmental drivers, such as diet (ie lower in-
take of fresh fruits/vegetables and higher intake of ultra-processed 
foods rich in animal protein and fat, additives and emulsifiers), 
medication/surgery (eg early life course exposure to antibiotics, ap-
pendectomy/tonsillectomy), and perhaps increased sanitation and 
hygiene resulting in loss of immune tolerance. Cigarette smoking 
was the first environmental risk factor for Crohn's disease.23 Crohn's 
disease is associated with smoking14 but nonsmoking is associated 
with ulcerative colitis.13,14 Notably, the first presentation of ulcera-
tive colitis is associated with smoking cessation, implying that early 
smoking suppressed the colitis.21 Some studies have reported a 
gender association, where smoking delayed the onset of the disease 
only in men or having more protection in females at diagnosis.21 In 
patients with ulcerative colitis, smoking has been shown to reduce 
relapses, hospitalisations, the need for oral corticosteroids and im-
munosuppressants, also the risk of colectomy and, in some studies, 
proximal disease extension.21,28 The effect of smoking on relapse in 
ulcerative colitis is best illustrated in the prospective, population-
based inception cohort study of patients from seven European coun-
tries and Israel who were followed up for 10 years.29 The mechanism 
of protection is not clear and studies of nicotine in the treatment 
of ulcerative colitis were limited and the adverse effects were com-
mon.20 It is important though to mention that some studies failed 
to identify beneficial effect of smoking on the course of ulcerative 
colitis.30,31 A recent study on extraintestinal manifestations (EIM) 
in inflammatory bowel disease patients revealed an association be-
tween smoking and EIMs in a dose-response relationship, in both 
ulcerative colitis and Crohn's disease patients.32 Moreover, a very 
recent study on clinical data covering a 12-year period, revealed that 
smoking cessation was not associated with worse disease course in 
ulcerative colitis patients.33
Smoking is known to increase the incidence of Crohn's disease 
by a factor of 1.834 to 4.635 and has negative impact on quality of 
life of Crohn's disease patients.36,37 The age of onset of Crohn's dis-
ease is bimodal: the first and largest peak occurs at young adulthood, 
the second smaller peak appears in people between 50 and 70 years 
of age.38 It has been suggested that smoking increases the risk of 
Crohn's disease onset in older group.31,39,40 It is clear that Crohn's dis-
ease patients who are active or ex-smokers have frequent relapses, 
more severe pain, higher rate of hospitalisation, worse response to 
treatment, greater need for surgery and greater risk of post- oper-
ative relapse.20,23,41-44 Interestingly, some studies have correlated 
smoking to ileal involvement and a lower prevalence of colonic 
Crohn's disease in active smokers.45-48 This raises the possibility that 
smoking might have a protective effect in colonic inflammation in 
both ulcerative colitis and Crohn's disease.20 Smoking cessation has 
shown to improve the course of Crohn's disease and therefore it has 
been recommended as a primary therapeutic approach.19,49 Vavricka 
and colleagues have shown recently that high altitude flights are a 
risk factor for relapse of both ulcerative colitis and Crohn's disease, 
with exposure to a hypoxic environment likely the key driver or mod-
ifying factor of inflammation50,51: Links to hypoxia may also explain 
the association between smoking and inflammatory bowel disease, 
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as smoking and hypoxic environments may synergistically act as po-
tent environmental risk factors for inflammatory.52,53
1.2 | Passive smoking and inflammatory 
bowel disease
Passive smoking or ‘second-hand’ smoking is the involuntary inhala-
tion of tobacco smoke (as from another's cigarette) especially by a 
nonsmoker, with children especially vulnerable. According to World 
Health Organisation, there is no safe level of exposure to second-hand 
tobacco smoke.54 Second-hand smoke causes serious cardiovascular 
and respiratory diseases, including coronary heart disease55 and lung 
cancer56 and it causes complications during pregnancy such as low 
birth weight and premature deaths.57-59 The development of inflam-
matory bowel disease has been studied in relation to prenatal smoke 
exposure and passive smoke exposure during childhood.21 A limited 
meta-analysis of key observational studies published 12 years ago, 
suggested that there was no strong association between prenatal ex-
posure to maternal smoke nor childhood passive smoke exposure and 
the development of Crohn's disease, nor was there any evidence that 
passive smoke exposure exerted a protective effect against ulcerative 
colitis.60 The authors expressed caution about the degree of heteroge-
neity between the studies used in the meta-analysis. Supporting these 
conclusions, Rigas and colleagues also showed no association between 
maternal smoking and inflammatory bowel disease.61 In contrast, 
there are other studies that show childhood exposure to smoke and/
or maternal smoking increasing risk of developing Crohn's disease,62-65 
or offering protection against ulcerative colitis.66 Maternal smoking, 
amongst other early life environmental factors, has been highlighted as 
a key influencing factor of disease course in Crohn's disease.67 Overall, 
this remains a very important issue for further research—at present, it 
is difficult to make definitive conclusions because there are very few 
studies performed to date.
1.3 | Smoking effects on the intestinal epithelium
The intestinal epithelium consists of multiple cell types (ie entero-
cytes, goblet cells, neuroendocrine cells, tuft cells, Paneth cells 
and M cells), and these can develop further into specialised sub-
sets.68,69 Its functions are absorption of nutrients and prevention 
of inflammatory conditions induced by exogenous factors, such as 
the commensal bacteria and foreign antigens.70 This is achieved by 
maintaining physical barrier (eg presence of intact tight junctions), 
synthesis of a mucus layer, secretion of antimicrobial peptides and 
immunoglobulin A, and by actively involved in immune cell regula-
tion, capable of internalising, processing, and efficiently presenting 
foreign antigens.71 The function of the intestinal epithelium in health 
and inflammatory conditions, such as inflammatory bowel disease, 
has been studied.70-73 During inflammatory bowel disease the bar-
rier integrity is compromised, there is an increasing tissue destruc-
tion and dysregulated mucosal inflammation.
1.3.1 | Tight junctions and epithelial barrier integrity
Epithelial cells of the intestine are sealed together with tight junc-
tions, which are positioned at the boundary of the apical and lat-
eral membrane surfaces. They maintain cell polarity, regulate flux of 
ions and solutes and provide epithelial barrier integrity, preventing 
bacteria/bacterial product translocation to underlying tissues.74 It is 
well-established that the dysfunction of the tight junction barrier 
system under inflammatory stress play a key role in the pathogenesis 
of Crohn's disease. Compromised tight junctions increase epithelial 
paracellular permeability and trigger an array of events including cel-
lular apoptosis, mucosal erosion and ulcers that contribute to intesti-
nal epithelium damage.75-77 Studies on airway epithelial barrier have 
shown that smoking can downregulate apical tight junction protein 
genes, impacting on epithelial barrier function and inducing perme-
ability of the airway mucosa.78 There are few studies relating to in-
testinal epithelium,79,80 which they mainly focus on nicotine effect.81 
An in vivo study on mice showed that cigarette smoke exposure was 
associated with intestinal barrier dysfunction such as increased per-
meability, bacterial translocation, intestinal villi atrophy and dam-
aged tight junctions, in the small intestine but not in the large.82
1.3.2 | Goblet cells and the mucus barrier
Goblet cells are epithelial secretory cells that secret mucins, a fam-
ily of glycoproteins that are the main component of mucus layers.83 
Mucus and other epithelial-derived factors play a critical role in 
host defence against invading bacterial pathogens,84,85 with mouse 
models of inflammatory bowel disease, whether chemically induced 
colitis (eg using dextran sodium sulphate [DSS], 2,4,6-trinitrobenze-
nesulfonic acid [TNBS] etc) or genetic mutations (eg Muc2, Tlr5 or 
Il10 knock-out transgenic strains), showing defective mucus barrier 
structure and function.86 In human ulcerative colitis, the layer is sig-
nificantly thinner or absent, whereas in Crohn's disease the colonic 
mucus layer is significantly thicker, as it was shown by measurement 
of mucus thickness in freshly resected colonic biopsies.87 Nicotine 
can induce mucus synthesis in explant culture of normal colonic tis-
sue.88 However, in a similar in vitro study, smoking habit had no ef-
fect on mucus synthesis in explants from healthy donors, suggesting 
that smoking could not explain differences in inflammatory bowel 
disease.89 The data showed though that mucus glycoprotein synthe-
sis is reduced in inactive ulcerative colitis, rising to normal levels in 
active disease and that synthesis is increased in Crohn's disease.89
1.3.3 | Paneth cells and antimicrobial activity
Paneth cells are highly secretory cells, lying at the bottom of intesti-
nal crypts, that produce antimicrobials to control gut microbial com-
munities.90 The role of Paneth cells in inflammatory bowel disease 
has recently been discussed in depth in a recent review, focusing 
on defective autophagy, reduced level of α-defensins in Paneth 
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cells and the resultant decreased levels antimicrobial activity.91 The 
effect of smoking on Paneth cell function has not been studied in 
depth. A key study in mice, has shown that intragastric exposure to 
smoking causes significant reduction in antimicrobial production by 
Paneth cells.92 In humans, tobacco consumption appears to cause 
defective Paneth cell function only in combination with genetic de-
fects, specifically with Autophagy related 16 like 1 gene T300A vari-
ant (ATG16L1T300A) associated with a high risk for Crohn's disease.93 
Crohn's disease patients of ATG16L1T300A genotype who are smokers 
have reduced number of Paneth cells and higher degree of apoptosis 
at the base of the crypts when compared to the wild type allele, 
whether they were smokers or nonsmokers.
1.3.4 | Intestinal transient receptor 
potential channels
The gut is extensively innervated, and its function is controlled by 
both the autonomous nervous system and its own enteric or intrinsic 
nervous system.94 Intestinal epithelial cells and neurons of the intrin-
sic nervous system have similar expression patterns of specific sen-
sory transient receptor potential channels; including TRPA1, TRPV1 
and TRPV4. These channels are tetramers, functioning to detect nox-
ious chemicals, toxins or irritants that might be present in the gut 
lumen, contribute to Ca2+ and Mg2+ absorption, induce the release 
of neuropeptides by afferent sensory neurons, as well as regulate 
innate immune responses and the production of tumour necrosis fac-
tor from mucosal macrophages and dendritic cells.94 TRP channels 
show increased expression in the colon of inflammatory bowel dis-
ease patients.95 As discussed by Allais and colleagues, similarities be-
tween inflammatory conditions in the lung and the intestine suggests 
that smoking may affect transient receptor potential channels in the 
gut in a similar manner to its actions on transient receptor potential 
channels in the lung epithelium—namely infiltration of immune cells, 
changes in the microbiome and induction of oxidative stress, but 
more work needs to be done to confirm this hypothesis.94
1.3.5 | Autophagy
One of the intestinal epithelium self-protective intracellular mecha-
nisms is autophagy, an evolutionary conserved catabolic process.96,97 
The role of autophagy in the pathogenesis and progression of inflam-
matory bowel disease has been reported extensively, with strong as-
sociation between variants of the autophagy-related gene ATG16L1 
and another key autophagy gene IRGM (encoding immunity-related 
GTPase family M protein), and susceptibility to Crohn's disease, and 
inability to function normally in recognition, handling and clearance 
of invading pathogens.97-99 Cigarette smoke exposure can induce 
autophagy in murine follicle-associated epithelium and in immune 
cells of the lymphoid follicle underlying Peyer's patches, suggest-
ing that smoke exposure might increase risk for Crohn's disease by 
causing epithelial oxidative damage, which needs to be repaired by 
autophagy.100,101 This could correlate with observations, using con-
focal laser endomicroscopy, of the earliest lesions of Crohn's disease 
in the Peyer's patches and therefore defective clearance of bacteria 
and increased inflammation.102,103 The effect of smoking and contri-
bution of specific mutations in autophagy-related genes, ATG16L1, 
IRGM and NOD2/CARD15 (an intracellular pathogen recognition re-
ceptor104) will be discussed further in a following section.
1.4 | Influence of smoking on the gut microbiota
Microbial colonisation of the gut begins immediately following birth 
and co-evolves with the host having a lifetime effect on an individu-
als’ health.105 The intestinal microbial communities (microbiota) of 
healthy donors, as assessed by metagenomic sequencing, is con-
sistently dominated by bacteria of two phyla, Bacteroidetes and 
Firmicutes.106 The composition of gut microbiota shows dynamic 
changes responding to various environmental factors, such as pH, 
oxygen levels/redox state, availability of nutrients, temperature, 
enabling various populations to thrive and exert different activities 
while interacting with their environment, including the host.107-109 
There have been numerous studies of the gut commensal bacte-
ria and their role in health and disease.110-112 Inflammatory bowel 
disease has been associated with decrease in gut microbial diver-
sity, an imbalance in the composition of host-associated microbiota 
(reduction in beneficial bacteria within the phyla Firmicutes and 
Bacteroidetes) and an increase shift towards potentially pathogenic 
microorganisms (especially mucosa-associated Enterobacteriaceae 
within the phylum Proteobacteria), a phenomenon often described, 
albeit controversially, as a ‘dysbiosis’.113-117 Imbalance in the com-
position of host-associated microbiota can lead to impaired epi-
thelial barrier function, defective bacterial recognition, antigen 
presentation and autophagy, dysregulated T cell responses leading 
to aberrant innate immune responses.118-121 Smoking may modify 
the microbiome of the oral, lung and gut, leading to disease includ-
ing periodontitis, asthma, chronic obstructive pulmonary disease, 
Crohn's disease, ulcerative colitis and cancer.122-125 Huang et al, 
highlight that changes in the microbiota can be linked to the disease 
progression in the lung.122 The most important effect of cigarette 
smoking on the colon is a prominent shift in microbiome composition 
and activity.126 A population-based cross-sectional study in Korean 
smokers showed altered faecal microbiota composition in current 
smokers compared to those who had never smoked, with a lower ob-
served Firmicutes:Bacteroidetes ratio and lower relative abundance 
of Proteobacteria.127 Dysbiosis was also observed in the duodenal 
mucosa-associated microbiota of patients undergoing endoscopy 
for upper GI symptoms, iron deficiency or Crohn's disease, with in-
creased Firmicutes and lower relative abundance of Bacteroidetes 
and Actinobacteria in current smokers vs never smokers,128 as shown 
in Figure 1. Moreover, study of faecal samples from Crohn's patients 
with active disease, analysed using fluorescent in situ hybridisation 
targeting bacterial 16S ribosomal RNA, showed that smokers had 
luminal microbiota of significantly higher ratio Bacteroides:Provetella 
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genera than those patients who were nonsmokers; and similarly 
for healthy controls that smoked.129 Smoking cessation studies in 
healthy smokers followed over a 9-week period showed increases in 
phyla Firmicutes and Actinobacteria, and decreased Bacteroidetes 
and Proteobacteria.130,131 However, there are still several limitations 
in studying the gut microbiome, like difficulties to culture in vitro 
several bacterial species, differences of bacterial proportions in dif-
ferent parts of gastrointestinal tract and environmental influences. 
As a consequence, the exact relationship between smoking and mi-
crobiome alteration remains to be further explored. Nevertheless, 
the microbiota has been recognised as an important target for thera-
peutic interventions, such as the use of antibiotics, prebiotics, probi-
otics and faecal microbiota transplantation.118
1.5 | Inflammatory bowel disease, the immune 
system and the influence of smoking
An impaired immune response in inflammatory bowel disease pa-
tients is essential to perpetuate intestinal inflammation.132 Smoking 
affects both adaptive and innate immunity and plays dual roles in 
regulating immunity by either exacerbation of pathogenic immune 
responses or attenuation of defensive immunity.133-135
1.5.1 | Adaptive immunity
A dysregulated intestinal T cell response is observed in inflamma-
tory bowel disease patients. T cell profiling studies on biopsies 
taken at time of diagnosis have revealed that inflammatory bowel 
disease patients have higher percentage of CD4+ T cells, T regula-
tory cells (Tregs) and central memory T cells (TCM), and a lower 
percentage of CD8+ T cells.136 Crohn's disease and ulcerative co-
litis though have different adaptive immune responses. Crohn's 
disease patients show a Th1/Th17 response with increased pro-
inflammatory cytokines, such as tumour necrosis factor, inter-
feron-gamma and interleukin-17A.16 In contrast, ulcerative colitis 
patients show a Th2 adaptive immune response, with high levels 
of interleukin-4, interleukin-13 and interleukin-14.17 Smoking in-
duces the inflammatory phenotype of inflammatory bowel disease 
towards a Th-1 response.137 Experiments in rodents have shown 
that cigarette smoke exposure can cause colitis, mainly mediated 
by Th-1 response, with interferon-gamma CD4+ T cells having 
detrimental role.137 Nicotine modulates the response of mucosal 
T cells towards a Th-1 phenotype via nicotinic acetylcholine re-
ceptors, which might explain the beneficial effect of smoking 
seen for ulcerative colitis patients.138 It has also been suggested 
that nicotine has a protective role, ameliorating DSS-induced 
colitis through blockade of signal transducer and activator of 
transcription 3 (STAT3) activation, and consequent proliferation 
of T-lymphocytes.139 T cell receptor sequencing on isolated mu-
cosal T cells has shown that Crohn's disease patients have variable 
clonal expansion of lamina propria CD8+ cells.140 Active smoking 
at the time of the surgery correlated with a high percentage of 
CD8+ clonal expansion, and persistence of similar T cell recep-
tor repertoire at postoperative endoscopy was associated with 
both smoking and disease recurrence.140 Whether in vitro or in 
vivo, exposure of human peripheral blood mononuclear cells to 
F I G U R E  1   Relative abundances of bacterial genera present in the duodenal (2nd part) mucosa-associated microbiota of patients with 
documented iron deficiency (ID, with and without anaemia), functional dyspepsia (FD) or FD with additional irritable bowel syndrome-like 
symptoms or Crohn's disease. Patients were grouped based on smoking status. Data were normalised via total sum scaling and is expressed 
as relative abundance. The 15 most abundant genera are displayed. Error bars represent standard deviation. * P < 0.005, FDR q < 0.05, 
Kruskal-Wallis with false discovery rate (FDR); # P < 0.05 ALDEx2 Wilcoxon rank test with Benjamini-Hochberg (BH) correction. o—order. 
The image was taken from ER Shanahan, A. Shah, N. Koloski, MM Walker, NJ Talley, M. Morrison and GJ Holtmann (2018) Microbiome; 
6:150, which is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creat iveco mmons.org/
licen ses/by/4.0/). No changes were made in this figure
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cigarette smoke showed that only peripheral blood mononuclear 
cells from Crohn's disease donors, and not from patients with ul-
cerative colitis, were functionally impaired, releasing lower levels 
of cytokines (eg interleukin-8, interleukin-12) and prostaglandin 
E2 and showing defective sensitivity to antioxidants, by releasing 
lower levels of heat shock protein 70.141 Another key study, has 
demonstrated that smoking may alter the composition of murine 
gut-associated lymphoid tissue, leading to a dramatic increase of 
CD4+,CD8+ T cells, and dendritic cells within Peyer's patches of 
the terminal ileum.142 This observation could explain why Crohn's 
ileitis is negatively affected by smoking. Analysis of small intestinal 
immune cell populations in a mouse model of short-term cigarette 
smoke exposure followed by DSS-induced colitis, identified that 
smoking induces intestinal inflammation via increase in Th17 cells, 
which further promote the recruitment of neutrophils by secret-
ing Interleukin-17A.143 The combination of use of Interleukin-17 
knockout and blocking anti-interleukin-17 antibodies revealed 
that the Th17 cells precede and are responsible for recruitment of 
neutrophils to the intestine.
1.5.2 | Innate immunity
Our innate immune system comprises of macrophages, dendritic 
cells, neutrophils and natural killer T lymphocytes, as well as type 
1-3 innate lymphoid cells that express the interleukin-23 recep-
tor (IL-23R), all major players in the pathogenesis of inflammatory 
bowel disease.144 These cells can sense and respond to conserved 
structural motifs on microorganisms, known as pathogen-associated 
molecular patterns, and act as antigen-presenting cells (APCs), pre-
senting antigen to T and B cells promoting adaptive immunity. They 
are phagocytotic and produce chemo-attractants and cytokines to 
regulate the immune response.134
Natural killer T lymphocytes secrete interleukin-13, a cytokine 
which causes damage to the epithelium, and that has an auto-
crine action, stimulating further natural killer T cell function.145 
However, Montbarbon and colleagues have shown clearly that 
smoking can improve DSS-induced colonic inflammation, par-
tially by causing a marked recruitment of invariant natural killer T 
lymphocytes (iNKT), possibly the iNKT2 subpopulation based on 
the cytokines detected.146 Invariant Natural Killer T lymphocytes 
are differentiated in the thymus, and they appear to be four sub-
types based on their cytokine expression; iNKT1 (tumour necrosis 
factor, interferon-γ, interleukin-4), iNKT2 (interleukin-4, nterleu-
kin-5, interleukin-13), iNKT17 (interleukin-17, interleukin-22, tu-
mour necrosis factor, granulocyte-macrophage colony-stimulating 
factor) and iNKT10 lymphocytes (interleukin-10).147 Different in-
variant natural killer T cell subsets are enriched in distinct tissues, 
for example iNKT2 cells populate several sites including the lung 
and spleen, but they are uniquely more abundant in mesenteric 
lymph nodes.148
Dendritic cells are found throughout the gut, including in the 
lamina propria, within isolated lymphoid follicles and the lymphoid 
tissue underlying Peyer's patches, and in mesenteric lymph nodes.149 
As it has been discussed recently, intestinal dendritic cells are im-
portant for maintenance of immune tolerance to the commensal mi-
crobes and dietary antigens.132 In patients with inflammatory bowel 
disease, dendritic cells are attracted and accumulate at the inflam-
matory sites. Dendritic cells from mesenteric lymph nodes of pa-
tients with Crohn's disease preferentially induce the Th1 response.67 
And the myeloid dendritic cells from mesenteric lymph nodes of pa-
tients with Crohn's disease produce high levels of interleukin-23 and 
low levels of interleukin-10.150 In vitro exposure of dendritic cells to 
crude cigarette smoke extract had a differential effect on phenotype 
and function of dendritic cells derived from both Crohn's disease and 
ulcerative colitis patients, with increasing T cell proliferation and Th1 
polarisation seen in Crohn's disease, and increased levels of fork-
head box P3-positive (Foxp3+) T cells and decreases in the Th1 sub-
set observed in ulcerative colitis samples.151
Intestinal macrophages are the most abundant mononuclear 
phagocytes within the intestine, especially in the colon, where they 
represent approximately 20% of all leucocytes.152,153 These resident 
intestinal macrophages are not typical antigen presenting cells, in 
that they do not secrete proinflammatory cytokines.141 In inflamma-
tory bowel disease, the dynamics of blood monocyte differentiation 
into resident intestinal macrophages is likely altered.154 Animal mod-
els of colitis show increased infiltration of monocytes and imma-
ture macrophages into the gut mucosa, which during inflammation 
subsequently differentiate into mature, proinflammatory macro-
phages and where they produce a large amount of proinflammatory 
mediators, such as tumour necrosis factor, interleukin-6 and nitric 
oxide.155 A study on myeloid cell populations isolated from either 
human colonic inflammatory bowel disease biopsy specimens or 
murine DSS- induced colitis tissue samples has identified that the 
macrophage-monocyte balance within the colon is also altered 
during colitis, with pro-inflammatory blood monocytes increasingly 
recruited to the lamina propria.156 Moreover, in vitro infection of 
monocyte-derived macrophages with various strains of Escherichia 
coli showed that the Crohn's disease-derived macrophages were 
dysfunctional, allowing intramacrophage persistence/ survival of 
all Escherichia coli strains tested, including the non-invasive K-12 
strain.157,158 However, other studies contradict these data, by show-
ing that Crohn's disease-derived macrophages are not defective 
at killing unless they have a genetic polymorphism. It is rather the 
innate ability of the Crohn's disease associated Escherichia coli to 
survive and replicate whereas the non-invasive K-12 strain is killed 
or mildly persistent.159 The effect of smoking on macrophages has 
been studied mainly in the context of the lung and smoking-related 
lung disease. Listeria infection experiments on alveolar macrophages 
showed that those macrophages derived from smokers had no bac-
tericidal or bacteriostatic activity.160 Also, alveolar macrophages 
from smokers showed defective autophagy and therefore aberrant 
clearance of internalised pathogens.161 Work from our lab has re-
cently shown that peripheral blood monocyte-derived macrophages 
from active smokers (mainly Crohn's disease patients) show hyper-
activation of the transcription factor Nuclear factor kappa B (NF-κB), 
1274  |     PAPOUTSOPOULOU eT AL.
releasing higher amounts of proinflammatory cytokines upon stim-
ulation with bacterial lipopolysaccharide in vitro, compared to mac-
rophages of nonsmokers.162 Multivariate analysis demonstrated that 
this phenotype did not correlate with disease severity, activity or 
disease status, nor type of medication, but it was only correlated 
with smoking status of Crohn's disease patients.
1.5.3 | Interaction between the immune system and 
intestinal microbiota
Physically, the epithelial barrier and the mucus layer(s), along with 
secretory IgA and anti-microbial peptides (eg defensins/cryptdins, 
lysozyme, cathelecidin etc), limit contact of bacteria to underlying 
immune cells.163-165 A major shift in the composition of the com-
mensal community can result in overgrowth of invasive pathogenic 
microbes, as discussed in detail by Littman and Palmer.163 The con-
cept that Escherichia coli are involved in the pathogenesis of inflam-
matory bowel disease is supported by multiple studies demonstrating 
intramucosal or mucosa-associated Escherichia coli in patients with 
Crohn's disease166-169 and in ulcerative colitis,170,171 and defective 
processing of intracellular bacteria by the innate immune cells. The 
gut microbes also indirectly, via intestinal mononuclear phagocytes, 
regulate the function of innate lymphoid cells (ILCs) which by produc-
ing interleukin-22 regulate the function of Paneth cells, enhance the 
proliferation of Lgr5+ stem cells and influence the adaptive immune 
responses.172 There is also literature on how specific components 
of gut microbiota and their metabolites shape the balance of Th17 
cells and Tregs.173 As an example, gut microbiota-derived metabolites 
adenosine-triphosphate and short-chain fatty acids were shown to 
stimulate the differentiation and development of Th17 and Tregs, re-
spectively.174,175 Based on what we know so far about the effects of 
smoking on either the immune system or the intestinal microbiota, 
we could hypothesise that it could impact on their mutual interac-
tions and consequently on the pathogenesis of inflammatory bowel 
disease.
1.6 | Cigarette smoke constituents and mucosal 
cell responses
Cigarette smoke is composed of gas and tar (or particulate) phases and 
contains >5000 chemical constituents22 Substances in the gas phase, 
such as carbon monoxide and light aldehydes, can pass through the 
airway epithelial barrier, enter the systemic circulation via the pulmo-
nary circulation, increasing systemic oxidative damage and leading to 
the development of cigarette smoking-related diseases.23,176-178 On 
the other hand, compounds such as nicotine, polycyclic aromatic 
compounds, nitrosamines and heavy metals are predominantly found 
in the tar phase, being absorbed by mucous membranes, skin, alveoli 
and the gastrointestinal system.42 A summary of smoke constituents 
that have been studied in relation to gastrointestinal inflammatory 
disease, as well as their major cellular targets/interactions/actions 
are presented in Table 1. Among all the constituents described, 
nicotine and carbon monoxide have gained greatest interest due to 
their beneficial effects as highlighted in a number of studies.23,179-181 
Nevertheless, the overall results are controversial and clinical trials do 
not support a positive role for nicotine-based treatment approaches 
TA B L E  1   Summary of cigarette smoke constituents and their effects on the intestinal mucosa
Constituent Cell type affected Action Ref
Nicotine Macrophage, dendritic cells Activation of nicotinic receptors α7 leads to decreased production 
of pro-inflammatory cytokines, both in vitro and in vivo
249,250
Endothelium of colonic 
microvessels
Inhibits MAdCAM-1 expression and leucocyte recruitment 251
Intestinal epithelium Mucus (mucin) synthesis and secretion 70
Acrolein Goblet cells Hyperplasia 252
Intestinal epithelium Disrupts tight junctions, causes cell death 253
Gut microbiota Increased Firmicutes and decreased Bacteroidetes 254
Human BEAS-2B and A549 
cell lines
ACR-histone adduct formation and inhibition of histone acetylation 255
Polycyclic aromatic 
hydrocarbons
Colonocytes Oxidative DNA damage, activation of AHR transcription factor, 
carcinogenesis
256
Carbon monoxide Macrophages, Dendritic cells Increased bacterial clearance. 23,178,257-259
Colonic myofibroblasts Alters interferon-γ signalling. Inhibits nitric oxide production via 
IRF-8.
Induction of FGF15 and intestinal epithelial restitution
183
Reactive oxygen 
species
Intestinal epithelium Induce proinflammatory cytokine production. Cause lipid 
peroxidation and other cell membrane constituents.
260
Abbreviations: MAdCAM-1, mucosal addressin cell adhesion molecule-1; ACR-histone, acrolein-histone; AHR, aryl hydrocarbon receptor; IRF-8, 
interferon regulatory factor 8; FGF15, fibroblast growth factor 15.
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for ulcerative colitis.20,182 Carbon monoxide has been shown to en-
hance intestinal epithelial restitution, having anti-inflammatory ef-
fects and modulating T-cell differentiation and activation, including 
inhibiting Th-17 cell formation.183 More recently, heme-oxygenase 1 
(HMOX1), the enzyme that metabolises heme to ferrous iron (Fe2+), 
biliverdin and carbon monoxide, has been suggested as key modula-
tor of inflammation in the intestine.184 One major issue in developing 
carbon monoxide based therapeutics, is its delivery in a pharmaceuti-
cally acceptable form, although there are a number of carbon monox-
ide pro-drugs in development.185
1.6.1 | Hypoxia
Chronic cigarette smoke exposure has shown to cause systemic 
hypoxia that affects the function of the, driving increased colonic 
tissue hypoxia and altered mucosal microvasculature, both common 
features of inflammatory bowel disease.186 An in vivo mouse model 
of chronic cigarette smoke exposure demonstrated induced histo-
logical and inflammatory changes in the colon.186 In the same study, 
smoke exposure predisposed to more severe TNBS-induced colitis, 
higher severity of pathology and increased levels of pro-inflamma-
tory cytokines. Another study examining levels of angiotensinogen 
in human ileal biopsy tissue, at both the messenger RNA and pro-
tein level, revealed reduced angiotensinogen levels in ileal Crohn's 
disease patients who were smokers implicating the mesenteric vas-
culature and mucosal hypoxia as co-factors in ileal Crohn's disease 
pathogenesis.52
1.6.2 | Nitric oxide
Nitric oxide is synthesised by nitric oxide synthase and is an unsta-
ble molecule.187 In physiological conditions, nitric oxide is produced 
by constitutively expressed nitric oxide synthase (cNOS) in the en-
dothelium or within the enteric nervous system of the gastrointes-
tinal tract. The low levels of nitric oxide protect against intestinal 
mucosal damage, promoting repair of epithelial erosions and ulcer 
healing. In pathological situations though, there is activation of in-
ducible nitric oxide synthase (iNOS) which produces nitric oxide 
for long periods of time (hours to days), having detrimental effects 
via potentiation of the adverse actions of other reactive oxygen 
species.187,188
1.6.3 | Reactive oxygen species
Reactive oxygen species are chemically unstable reactive free 
radicals that contain oxygen, including peroxides (such as hydro-
gen peroxide (H2O2)), the superoxide anion (O2
•−) and hydroxyl 
radicals (OH•), that cause oxidative damage to cellular membrane 
lipids, proteins, enzymes and nucleic acids such as deoxyribonucleic 
acid (DNA) and ribonucleic acid (RNA).177 Most cell types, during a 
variety of biochemical processes, are capable of generating reactive 
oxygen species, but the major sources are from phagocytic cells (via 
action of phagocyte nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase, that upon stimulation generates superoxide ani-
ons) and various epithelial cell types, including intestinal cells.189 
Reactive oxygen species, and consequent oxidative stress, are 
major characteristics of inflammatory bowel disease development 
and progression and have been discussed extensively in previous 
reviews.190-193 Cigarette smoke is known to contain stable gaseous 
free radicals, reactive oxygen species and tar semi-quinone radicals, 
that either directly affect living cells, or indirectly by dysregulation 
of cascades such autophagy that lead to further production of reac-
tive oxygen species.177,194
1.7 | Gene polymorphisms determining 
inflammatory bowel disease susceptibility and 
influence of smoking
Genetic predisposition in inflammatory bowel disease patients, ob-
served almost 30 years ago by identifying familial risks, is still an ex-
citing area of clinical and basic research.195-198 In this section, we will 
discuss the genetic defects that are linked to inflammatory bowel 
disease and the differential gene expression observed in cell types 
that are major players, such as immune and intestinal epithelial cells.
1.7.1 | Genetic polymorphisms
There are numerous genome-wide association studies (GWAS) and 
large meta-analyses that have identified susceptibility risk polymor-
phisms of genes strongly associated with inflammatory bowel disease. 
Single nucleotide polymorphisms (SNPs) are the most common type of 
genetic variation. Single nucleotide polymorphisms are of great impor-
tance because they may influence gene expression, messenger RNA 
stability, and subcellular localisation of messenger RNAs and/or pro-
teins and hence may produce disease.199 More than 200 genes have 
been identified by these approaches and most of them are linked to 
Crohn's disease.200-204 These include genes that encode, cytokines, 
cytokine receptors, autophagy-related proteins, signalling molecules 
and other proteins with enzymatic or not activities. Extensively studied 
examples are the genes NOD2/CARD15, encoding the nucleotide-bind-
ing oligomerisation domain-containing protein 2/caspase recruitment 
domain-containing protein 15, two autophagy-related genes ATG16L1 
and IRGM and the IL23R, encoding the receptor for the interleukin-23 
cytokine. Smoking has been associated with genetic polymorphisms 
and higher risk for surgery.205 Six single nucleotide polymorphisms 
associated with smoking quantity and behaviour were analysed in a 
Swiss cohort and were combined to form a risk score. Further analysis 
revealed that in Crohn's disease patients who smoke, the number of 
surgeries was associated with the genetic risk score.205 Crohn's dis-
ease smokers who were of the ATG16L1T300A genotype, showed sig-
nificantly shorter time to recurrence after surgery.93 The strongest 
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genetic defects were associated with smoking quantity and nicotine 
dependence and genome-wide association studies have discovered 
high-risk single nucleotide polymorphisms close to nicotinic acetyl-
choline receptor subunits.205,206 The number of inflammatory bowel 
disease-associated genes that have been studied and found to be af-
fected by smoking is presented in Table 2. It seems that there is no de-
fined group of genes or cellular pathway, nor process correlating with 
smoking status. Instead, there is a wide spectrum of genes including 
major histocompatibility complex proteins, cytokines, cytokine recep-
tors, neurotransmitters, and metabolic enzymes.
1.7.2 | Dysregulation of gene expression
Gene expression is not only affected by the presence of single nu-
cleotide polymorphisms, but also by mutations, such as deletions or 
duplications, as well as by dysregulation of upstream pathways and 
exogenous factors. Transgenic animal models, eg gene knockouts, 
have been extensively used to study the effect of gene expression on 
health and disease. Well-known examples in the field of intestinal in-
flammatory diseases are the NOD2-/-,207 Il10 -/-,208 Il10R-/-,209 ITGA4210 
and many more. Deficiencies of human IL10 and IL10R genes are also 
well-established defects linked to inflammatory bowel disease.211,212 
Smoking has been shown to interfere with gene expression in studies 
on genetically modified mice, as well as on human population studies 
focused on inflammatory bowel disease cohorts. In vitro experiments 
in intestinal epithelial cell-lines showed that cigarette smoke extract 
delayed TNF-induced NOD2 mRNA expression and that this resulted in 
abnormal NF-κB regulation and cytokine production.213 Chronic ciga-
rette exposure of mice induced mRNA expression of Muc2 and Muc3 
in the ileum, whereas Muc4 increased in the distal colon. Furthermore, 
increased chemokine (C-X-C motif) ligand 2, Cxcl2, and decreased 
interferon-γ, Ifng, in the ileum were observed.126 Microarray analysis 
of colonic biopsies identified dysregulation of the β-defensin-2 gene, 
HBD2, whose expression was augmented in consequent in vitro cul-
tures by the addition of nicotine.214 Quantitative real-time polymerase 
chain reaction performed on inflamed vs non-inflamed biopsies from 
ileal Crohn's disease patients showed that active smokers had down-
regulated angiotensinogen mRNA levels.52 In a recent cross-sectional 
study, the mRNA levels of various cytokines were measured in mucosa 
biopsies from inflamed and no-inflamed areas in inflammatory bowel 
disease patients.215 They found that smokers with Crohn's disease 
TA B L E  2   Genetic risk alleles and smoking correlation in inflammatory bowel disease
Gene Observation Reference
Ulcerative colitis and smoking - associated genes
HSPA6 Induced by smoking and shown to stabilise the anti-apoptotic protein B-cell lymphoma extra-
large (Bcl-XL)
261
HLA HLA-DRB1*15:02 was associated with ulcerative colitis in never smokers and HLA-DQB1*06 was 
associated with ulcerative colitis in active smokers
262
GSTP1 Former smokers who were heterozygous or homozygous for polymorphisms near the glutathione 
S-transferase P1 gene had increased risk of ulcerative colitis
263
TRIM39, HLA, GRB10, 
PTPLA, ADAM1, SMAD3
An analysis of 55 immunochip-wide data sets identified SNPs whose association with risk for 
inflammatory bowel disease is modified by tobacco smoking
264
Crohn's disease and smoking - associated genes
CYP2A6 Current smoking was associated with Crohn's disease only in individuals with AG/GG genotype 263
TNFR2 In Crohn's disease, the TNFR2 polymorphisms were negatively associated with smoking at 
diagnosis.
265
TUCAN (CARD8)
NOD1, IBD5
TNFSF15
Highly significant association between Crohn's disease and a diagnostic panel of smoking status 
that includes TUCAN, NOD2, IBD5, NOD1 and TNFSF15
266
PLAG2, POMC, LYG2 An analysis of 55 immunochip-wide data sets identified single nucleotide polymorphisms whose 
association with risk for inflammatory bowel disease is modified by tobacco smoking
262,264
NOD2/CARD15 DSS-induced colitis in Nod2-/- mice showed strong protective role of interleukin-10 on intestinal 
homeostasis in response to tobacco smoking.
High absolute risks of Crohn's disease can be obtained by incorporating information on smoking, 
family history and NOD2/CARD15 mutations
264,267,268
IL10 DSS-induced colitis in Il10-/- mice showed strong protective role of interleukin-10 on intestinal 
homeostasis in response to tobacco smoking
198,264
SP Smoking habit was significantly associated with substance P levels in Crohn's disease 269
IL23R A strong additive interaction exists between IL23R single nucleotide polymorphisms and smoking 
behaviour resulting in a dramatic increase in Crohn's disease risk
270
Abbreviations: HLA-DRB1, HLA class II histocompatibility antigen, DRB1 beta chain; HLA-DQB1*06, HLA class II histocompatibility antigen, DQ beta 
1 chain.
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had significantly higher TNF mRNA levels in inflamed mucosa com-
pared with nonsmokers. Also, in smokers with ulcerative colitis, they 
observed significantly higher IL10 mRNA levels in non-inflamed mu-
cosa.215 Another study, on expression on colonic detoxification genes, 
showed that of the 244 detoxification genes investigated, 65 were dys-
regulated in ulcerative colitis patients in comparison to healthy con-
trols or Crohn's disease patients.216 Of the 65 genes dysregulated, 43 
were brought back to normal levels in biopsies of ulcerative colitis cur-
rent smokers in remission and in colonic explants of ulcerative colitis 
patients exposed to cigarette smoke extract, supporting the protective 
role of smoking in ulcerative colitis.216
1.8 | Smoking and epigenetic modifications in 
inflammatory bowel disease
Epigenetic modifications are heritable changes that affect gene ex-
pression or cellular characteristics and processes. Smoking is an en-
vironmental factor that can cause epigenetic modifications and this 
effect has been studied extensively in many inflammatory diseases 
as discussed previously.25 Three major types of epigenetic modifi-
cations; (a) methylation, (b) histone modifications and (c) noncoding 
RNA, and current knowledge in relation to intestinal inflammation 
and smoking will be discussed in the following sections.
1.8.1 | DNA methylation
DNA methylation is a physiological mechanism of gene suppres-
sion that maintains pluripotency, X-chromosome inactivation and 
genomic imprinting.217 The methylation patterns are controlled by 
DNA methyltransferases (DNMTs) as well as CpG methyl binding 
proteins (MBD).218 DNA methyltransferases comprise a family of 
tightly regulated enzymes that are responsible for the transfer of 
methyl group on the fifth carbon of cytosine residues in DNA within 
CG dinucleotides, the so called methylation process.219 Among the 
epigenetic mechanisms, DNA methylation has been widely studied 
with respect to smoking because it causes dysregulated global and 
gene-specific DNA methylation. One of the first studies on ulcera-
tive colitis patients performed methylation analysis on mucosal bi-
opsies and identified increased methylation of promoter regions.220 
More recently, a study on methylation pattern on blood samples from 
paediatric inflammatory bowel disease donors indicated that Crohn's 
disease-associated patterns of DNA methylation observed are a re-
sult of the inflammatory features of the disease and are less likely 
to contribute to disease development or progression.221 Comments 
on that study highlighted the positive points, especially the identi-
fication of a target gene RPS6KA2 (encoding the enzyme ribosomal 
protein S6 kinase alpha-2), that has been shown in previous study 
to be significantly hypomethylated in inflammatory bowel disease 
across several independent paediatric and adult cohorts.222 There 
are numerous publications linking DNA methylation to inflamma-
tory bowel disease, identifying epigenetic methylation signatures on 
genes such as tumour necrosis factor, TNF and human alpha defensin 
5, DEFA5,223 or tyrosine-protein kinase TXK,TXK,224 Interestingly, 
all the studies in the field of intestinal inflammation that focus on 
smoking and DNA methylation are linked to colorectal cancer. Both 
inflammatory bowel disease and CpG island methylation confer high 
risk for malignancies, as it has been discussed in several reviews over 
the last two decades.225-232
1.8.2 | Histone modifications
Histones are basic proteins that interact with negatively charged 
DNA to form the compact nucleosomes, the basic unit of the chro-
mosomes. There are several histone modifications which affect 
chromatin structure and gene expression. These modifications in-
clude methylation, acetylation, phosphorylation, ubiquitination, su-
moylation, crotonylation, ADP-ribosylation and deamination.233,234 
The role of histone modifications in inflammatory bowel disease is 
very limited. A recent review by Ray and Longworth discusses the 
most updated information about histone modifications and their 
role in intestinal epithelium and T cells.235 Moreover, the microbi-
ome and some of its metabolites, eg short-chain fatty acids, poly-
amines, polyphenols and vitamins, have been shown to affect the 
genome via histone modification,236,237 a function which is modu-
lated further by dysbiosis that takes place during intestinal inflam-
matory conditions.238
1.8.3 | Noncoding RNAs
The microRNAs (miRNAs) are short noncoding RNAs that affect 
gene expression post-transcriptionally.239 They function via base-
pairing with complementary sequences within mRNA molecules 
and as a result, these mRNA molecules are silenced.240 Under 
physiological conditions, microRNAs contribute to intestinal ho-
meostasis by regulating intestinal epithelial differentiation, archi-
tecture and barrier function.241 There is extended literature though 
about the role of various microRNAs in intestinal inflammation and 
the risk of cancer development. One study showed that nicotine 
increased the levels of miR-124 in epithelial cells and infiltrated 
T cells of mice during DSS-induced colitis.139 Another category 
of noncoding RNAs are the long noncoding RNAs (lncRNAs).242 
They have been shown to affect the intestinal epithelial barrier by 
modulating the translation of the tight junction mRNAs.243 Long 
noncoding RNAs are also involved in pathogenesis of inflamma-
tory bowel disease and this topic is discussed by Yarani and col-
leagues in a recent review.244
Smoking has been shown to affect all three types of epigenetic 
modifications.24,245-247 In a systematic review that analysed 14 epig-
enome-wide association studies of smoking exposure it was shown 
that DNA methylation is a reversible modification and after smoking 
cessation, most of the genes returned to physiological levels within 
5 years.248 More recently, another systematic review summarised a 
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10-year literature, including all types of studies in the field of smok-
ing and chronic obstructive pulmonary disease, identifying differen-
tially expressed genes and microRNAs in smokers and their potential 
to be biomarkers, highlighting the transgenerational effects of ma-
ternal and paternal smoking on offspring.25
1.9 | Implications for pathogenesis—definition 
research agenda
As it is discussed above, cigarette smoking affects inflammatory 
bowel disease pathogenesis at various levels. It targets the genetic 
information (DNA and RNA), modifies structures and protein func-
tions, alters pathways and processes, effects that are amplified at 
the tissue and organ levels. The effects of smoking, summarised in 
Figure 2, are caused by a variety of chemicals existing in the gas 
and tar phase, they are systemic and local, and they can be direct 
or indirect. The oxidative damage of lipids, proteins and DNA, the 
activation of the nicotinic acetylcholine receptor and the transient 
receptor potential channels on intestinal epithelium or on neurons 
are few of the direct effects. Examples of indirect effects are the 
major changes in the microbiome constitution and the epigenetic 
modifications on immune cells and intestinal epithelium. It is still 
unknown whether cigarette smoke causes specific epigenetic al-
terations in the intestinal commensal bacteria. This area needs 
to be explored further because the intestinal microbes and their 
products are in a constant interaction with the host tissues and 
have the potential to modify their functions. The research inter-
est has started to focus on epigenetic changes that could explain 
the phenotypic differences within inflammatory bowel disease. 
Evolution of sequencing approaches and their analyses will help 
identify cell-specific epigenetic changes and how these affect 
cellular functions and interactions within tissues and with other 
organ systems or organisms.
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